 - Clinical outcome measurements Each patient will give written consent for inclusion in the study. This prospective, single-centered, randomized clinical trial is designed to enroll a total of 120 patients who meet the inclusion criteria, with approximate 60 patients in each group. Patients are allocated to a intravenous application of TXA or b intra-articular administration of TXA, with use of a computer-generated randomization table. 